Veterinary CRO and CDMO Market Report 2026

The veterinary cro and cdmo market size has grown strongly in recent years. It will grow from $7.53 billion in 2025 to $8.2 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to limited in-house r&d capabilities of veterinary companies, growing companion animal population, rising prevalence of animal diseases, early adoption of cdm/o services in developed regions, demand for innovative veterinary biologics and drugs.

The veterinary cro and cdmo market size is expected to see strong growth in the next few years. It will grow to $11.81 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing demand for contract research and manufacturing services, technological advancements in veterinary drug development, growth of veterinary biologics and pharmaceuticals, expansion of global regulatory compliance requirements, rising adoption of precision medicine for animals. Major trends in the forecast period include increasing outsourcing of veterinary drug development, expansion of preclinical and clinical trial services, growing demand for regulatory consulting services, adoption of advanced analytical and formulation services, rising focus on post-marketing surveillance and pharmacovigilance.

The rising level of pet ownership is expected to drive the growth of the veterinary CRO and CDMO market in the coming years. Pet ownership refers to the responsibility of an individual or household for the care, well-being, and management of a domesticated animal and represents a long-term legal and ethical commitment. The increase in pet ownership is driven by greater awareness of the emotional and health benefits associated with pets, as individuals increasingly seek companionship, stress reduction, and improved overall well-being through pet care. The veterinary CRO and CDMO market supports this trend, as a growing pet population increases demand for the development and manufacturing of veterinary drugs, vaccines, and therapies to safeguard pet health and safety. For example, in March 2025, the American Pet Products Association, a US-based non-profit organization, reported that 94 million US households owned at least one pet, compared with 82 million households in 2023. Therefore, the increasing prevalence of pet ownership is contributing to the growth of the veterinary CRO and CDMO market.

Leading players operating in the veterinary CRO and CDMO market are focusing on developing innovative service offerings, such as integrated multi-site CDMO networks with advanced sterile manufacturing, lyophilization, and specialized dosage capabilities, to streamline drug development lifecycles and accelerate compliant commercialization pathways. Integrated multi-site CDMO networks are coordinated platforms that bring together multiple manufacturing sites and specialized technologies - including sterile multidose systems, lyophilization, and flexible packaging - within unified operational and quality frameworks to deliver end-to-end pharmaceutical development and production services. For instance, in April 2025, Meribel Pharma Solutions, a UK-based full-service CDMO providing drug development, formulation, analytical services, sterile and semi-solid manufacturing, and packaging solutions, commenced operations with a network of 13 facilities across France, Spain, and Sweden. This network supports products from early-stage development through commercial-scale production and offers centers of excellence in oral solid dosage forms, preservative-free multidose systems, and lyophilization technologies for both human and veterinary health products.

In May 2023, Argenta, a Belgium-based contract research organization (CRO) and contract development and manufacturing organization (CDMO), acquired Midwest Veterinary Services Inc. for an undisclosed amount. This acquisition aims to enhance the service offerings of both companies, enabling them to provide a broader range of clinical research, product development, and manufacturing solutions. Midwest Veterinary Services Inc. is a US-based firm that specializes in veterinary CRO and CDMO services, concentrating on the development and testing of animal health solutions.

Major companies operating in the veterinary cro and cdmo market are Eurofins Scientific SE, Charles River Laboratories Inc., IDEXX Laboratories Inc., Elanco India Private Limited, Aenova Group, Taconic Bioscience Inc., knoell Germany GmbH, ClinVet International Pty Ltd., VetPharm Inc., Vetio Animal Health Company, Ridgeway Research Ltd., Drayton Animal Health Ltd., KLIFOVET GmbH, Cebiphar, Veterinary Research Management (VRM) Ltd., Vetspin Srl, STATKING Animal Health CRO, Arcoblu S.r.l., Syneos Health Inc., Pharmaceutical Product Development Inc., Inotiv Inc., Promega Corporation, Triveritas Ltd.

North America was the largest region in the veterinary CRO and CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary cro and cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary cro and cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the veterinary CRO and CDMO market by increasing costs for imported raw materials, APIs, and advanced laboratory equipment, particularly impacting development, manufacturing, and packaging segments in regions such as North America, Europe, and Asia-Pacific. Companion animal and livestock drug development services face the most significant impact. While tariffs have increased operational costs, they have also incentivized local manufacturing and process innovation, supporting regional service providers in reducing dependency on imports.

The veterinary cro and cdmo market research report is one of a series of new reports that provides veterinary cro and cdmo market statistics, including veterinary cro and cdmo industry global market size, regional shares, competitors with a veterinary cro and cdmo market share, detailed veterinary cro and cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary cro and cdmo industry. This veterinary cro and cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A veterinary CRO (Contract Research Organization) is a specialized service provider that conducts research and clinical trials to evaluate the safety and efficacy of veterinary drugs and healthcare products. On the other hand, a veterinary CDMO (Contract Development and Manufacturing Organization) is a specialized service provider that offers contract development and manufacturing services for veterinary drugs and healthcare products, assisting with formulation development, process optimization, and production.

The main services provided by veterinary CROs and CDMOs include discovery, development, manufacturing, packaging and labeling, and market approval and post-marketing. Drug discovery in the context of veterinary CDMO and CMO (Contract Manufacturing Organization) typically refers to early-stage research and development activities related to the identification and optimization of potential drug candidates on behalf of their clients. These services cover a broad spectrum of applications, including medicines, medical devices, pharmaceuticals, biologics, and others, for both companion animals and livestock animals.

The veterinary CRO and CDMO market includes revenues earned by entities through contract research, development, and manufacturing services. This encompasses the income generated by these entities for conducting preclinical studies, clinical trials, pharmacokinetics, and pharmacodynamics testing, toxicology studies, formulation development, process optimization, and manufacturing of veterinary drugs and healthcare products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.